Etravirine (ETR)

DRUG4 trials

Sponsors

Tibotec Pharmaceuticals, Ireland, National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare

Conditions

HIV InfectionsHuman Immunodeficiency Virus Type 1Infection, Human Immunodeficiency Virus

Phase 1

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

CompletedNCT01504841

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2013-03-14End: 2020-08-26Updated: 2021-11-02

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

CompletedNCT02063360

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2014-02-01End: 2014-05-13Updated: 2017-08-08

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

CompletedNCT04630002

ViiV HealthcareHIV Infections

Start: 2020-10-28End: 2021-10-02Updated: 2024-08-29

Phase 2

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

CompletedNCT00128830

Tibotec Pharmaceuticals, IrelandHuman Immunodeficiency Virus Type 1

Start: 2005-06-30End: 2008-08-31Updated: 2013-06-20

Related Papers

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.

2022-03-228 citations